Title:
CD33 ANTIBODIES AND USE OF SAME TO TREAT CANCER
Document Type and Number:
WIPO Patent Application WO/2013/173496
Kind Code:
A3
Abstract:
The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33. The monoclonal antibodies contain complementarily determining regions (CDRs) of SEQ ID NOs: 19, 20, and 21 in the heavy chain variable region and CDRs of SEQ ID NOs: 22, 23, and 24 in the light chain variable region.
Inventors:
SUTHERLAND MAY KUNG (US)
RYAN MAUREEN (US)
SUSSMAN DJANGO (US)
BURKE PATRICK (US)
JEFFREY SCOTT (US)
RYAN MAUREEN (US)
SUSSMAN DJANGO (US)
BURKE PATRICK (US)
JEFFREY SCOTT (US)
Application Number:
PCT/US2013/041209
Publication Date:
June 04, 2015
Filing Date:
May 15, 2013
Export Citation:
Assignee:
SEATTLE GENETICS INC (US)
International Classes:
A61K39/395
Foreign References:
| US20120082670A1 | 2012-04-05 | |||
| US20110206700A1 | 2011-08-25 | |||
| US20100158909A1 | 2010-06-24 | |||
| US20070190060A1 | 2007-08-16 | |||
| US20020022031A1 | 2002-02-21 |
Other References:
FELDMAN ET AL.: "Phase III Randomized Multicenter Study of a Humanized Anti- CD 33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 18, 20 June 2005 (2005-06-20), pages 4110 - 4116, XP009142408
Attorney, Agent or Firm:
LIEBESCHUETZ, Joe et al. (100 South Tyron StreetBank of America Plaza, Suite 400, Charlotte North Carolina, US)
Download PDF: